Non-small cell lung cancer and vindesine: A review

R. J. Gralla

Research output: Contribution to journalArticlepeer-review

2 Scopus citations


Vindesine is a new, semisynthetic vinca alkaloid that has shown activity against nonsmall cell lung cancer in phase II trials conducted at several institutions. Regimens giving vindesine weekly at 3 mg/m2 i.v. x 5 weeks have been associated with the highest response rates. The vinca alkaloid can be administered in full doses when given with cisplatin, and a major response rate of 43% has been reported for the combination. The development of new drugs continues to be a major priority in the investigation and treatment of lung cancer.

Original languageEnglish (US)
Pages (from-to)565-570
Number of pages6
JournalDrugs under Experimental and Clinical Research
Issue number5
StatePublished - Jan 1 1982

ASJC Scopus subject areas

  • Molecular Medicine
  • Pharmacology
  • Drug Discovery
  • Pharmacology (medical)


Dive into the research topics of 'Non-small cell lung cancer and vindesine: A review'. Together they form a unique fingerprint.

Cite this